Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

CompletedOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
Breast Cancer
Interventions
DRUG

palbociclib plus letrozole

palbociclib plus letrozole

Trial Locations (13)

260-8717

Chiba cancer center, Chiba

791-0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

730-8518

Hiroshima City Hiroshima Citizens Hospital, Hiroshima

003-0804

National Hospital Organization Hokkaido Cancer Center, Sapporo

860-8556

Kumamoto University Hospital, Kumamoto

362-0806

Saitama Cancer Center, Kita-adachi-gun

104-0045

National Cancer Center Hospital, Chuo-ku

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

892-0833

Hakuaikai Medical Corporation Sagara Hospital, Kagoshima

862-8655

Kumamoto Shinto General Hospital, Kumamoto

606-8507

Kyoto University Hospital, Kyoto

464-8681

Aichi Cancer Center, Nagoya

540-0006

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research, Osaka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04735367 - Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole | Biotech Hunter | Biotech Hunter